Discordant MRI/FDG-PET imaging for the diagnosis of borderline ovarian tumors

International Journal of Gynecological Cancer

Volumn 18, Issue 4, 2008, Pages 637-641

  Jung, D C ^a   Choi, H J ^a   Ju, W ^b   Kim, S C ^b   Choi, K G ^b  

^a National Cancer Center   (South Korea)

^b Ewha Womans University School of Medicine   (South Korea)

Author keywords

Borderline ovarian tumor; MRI; PET

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; DIAGNOSTIC IMAGING; DRUG TUMOR LEVEL; FEMALE; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; OVARY TUMOR; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; RETROSPECTIVE STUDY; TUMOR DIFFERENTIATION;

ADOLESCENT; ADULT; AGED; CARCINOMA; DIAGNOSIS, DIFFERENTIAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; OVARIAN NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PRECANCEROUS CONDITIONS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TUMOR BURDEN;

EID: 47649124498     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2007.01116.x     Document Type: Article

References (18)

1. Taylor HC. Malignant and semimalignant tumors of the ovary. Surg Gynecol Obstet 1929 48 : 204 30.
2. International Federation of Gynecology and Obstetrics. Classification and staging of malignant tumors in the female pelvis. Acta Obstet Gynecol Scand 1971 50 : 1 7.
3. Trimble CL, Trimble EL. Management of epithelial ovarian tumors of low malignant potential. Gynecol Oncol 1994 55 : S52 61.
4. Rice LW, Berkowitz RS, Mark SD et al. Epithelial ovarian tumors of borderline malignancy. Gynecol Oncol 1990 39 : 195 8.
5. Rieber A, Nussle K, Stohr I et al. Preoperative diagnosis of ovarian tumors with MR imaging: comparison with transvaginal sonography, positron emission tomography, and histologic findings. Am J Roentgenol 2001 177 : 123 9.
6. Outwater EK, Dunton CJ. Imaging of the ovary and adnexa: clinical issues and applications of MR imaging. Radiology 1995 194 : 1 18.
7. deSouza NM, O'neil R, McIndoe GA, Dina R, Soutter WP. Borderline tumors of the ovary: CT and MRI features and tumor markers in differentiation from stage I disease. Am J Roentgenol 2005 184 : 999 1003.
8. Cho SM, Ha HK, Byun JY et al. Usefulness of FDG PET for assessment of early recurrent epithelial ovarian cancer. Am J Roentgenol 2002 179 : 391 5.
9. Bristow RE, del Carmen MG, Pannu HK et al. Clinically occult recurrent ovarian cancer: patient selection for secondary cytoreductive surgery using combined PET/CT. Gynecol Oncol 2003 90 : 519 28.
10. Pannu HK, Bristow RE, Cohade C, Fishman EK, Wahl RL. PET-CT in recurrent ovarian cancer: initial observations. Radiographics 2004 24 : 209 23.
11. Gambhir SS. Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer 2002 2 : 683 93.
12. Takekuma M, Maeda M, Ozawa T, Yasumi K, Torizuka T. Positron emission tomography with 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancer. Int J Clin Oncol 2005 10 : 177 81.
13. Fenchel S, Grab D, Nuessle K et al. Asymptomatic adnexal masses: correlation of FDG PET and histopathologic findings. Radiology 2002 223 : 780 8.
14. 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) in diagnosis of ovarian cancer. Int J Gynecol Cancer 1999 9 : 117 22.
15. Risum S, Hogdall C, Loft A et al. The diagnostic value of PET/CT for primary ovarian cancer - a prospective study. Gynecol Oncol 2007 105 : 145 9.
16. Serov SF, Scully RE, Sobin LH. International histological classification and staging of tumors. Histologic typing of ovarian tumors, Vol. 9. Geneva : World Health Organization, 1973.
17. Barakat RR. Borderline tumors of the ovary. Obstet Gynecol Clin North Am 1994 21 : 93 105.
18. Kurokawa T, Yoshida Y, Kawahara K et al. Expression of GLUT-1 glucose transfer, cellular proliferation activity and grade of tumor correlate with [F-18]-fluorodeoxyglucose uptake by positron emission tomography in epithelial tumors of the ovary. Int J Cancer 2004 109 : 926 32.